Cancer Gene Therapy

Onyx Begins Testing Anticancer Agent

Published in Gene Therapy Weekly, March 17th, 1997

Onyx Pharmaceuticals Inc., Richmond, California, announced that it has expanded Phase I human clinical testing of the ONYX-015 anticancer agent to include patients with pancreatic cancer.

This is the second Phase I clinical trial that ONYX has initiated with ONYX-015. The first Phase I study, directed at head and neck tumors, began in April 1996.

ONYX-015 is a genetically engineered adenovirus that efficiently replicates in and kills tumor cells deficient in the p53 tumor suppressor gene product. Mutations in p53 are the most common type of genetic abnormality in cancer, occurring in more than 50 percent of human cancer cases, including more than...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry